IP Library Patent Application 12499051
Patent Application
App. No. 12/499,051

NAPHTHOQUINONE COMPOSITIONS WITH ANTI-AGING, ANTI-INFLAMMATORY AND SKIN EVEN-TONING PROPERTIES

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/499,051
Abstract

The present invention relates to methods and compositions comprising naphthoquinones such as 2,3-dimethylnaphthalene-1,4-dione, for the use of treating, regulating or preventing a skin condition characterized by oxidative stress or a degenerative process. Methods of preventing, lightening or reducing the appearance of visible and/or tactile discontinuities of the skin resulting from skin pigmentation or skin aging are also disclosed.

Claims (26)

1 . A cosmetic or dermatological composition comprising one or more naphthoquinones of formula I or their reduced form of formula Ia:

wherein

n is 0 to 4;

R 1 and R 2 are independently selected from (C 1 -C 8 )alkyl or (C 1 -C 4 )alkoxy;

each R 3 is independently hydrogen, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, halogen, or (C 1 -C 6 ) haloalkyl;

and mixtures thereof.

2 . The composition of claim 1 , wherein n is 0.

3 . A cosmetic or dermatological composition comprising a therapeutically effective amount of the composition of claim 1 and a pharmaceutically, dermatologically, or cosmetically acceptable carrier.

4 . The cosmetic or dermatological composition of claim 1 , comprising 2,3-dimethylnaphthalene-1,4-dione of formula Ib, its reduced form 2,3-dimethylnaphthalene-1,4-diol of formula Ic, or a mixture thereof:

5 . The cosmetic or dermatological composition of claim 4 , comprising 2,3-dimethylnaphthalene-1,4-dione (formula Ib).

6 . The cosmetic or dermatological composition of claim 4 , comprising 2,3-dimethylnaphthalene-1,4-diol (formula Ic).

7 . A cosmetic composition comprising a therapeutically effective amount of the composition of claim 4 and a pharmaceutically or cosmetically acceptable carrier.

8 . A method of regulating or preventing a skin condition wherein the skin condition is characterized by oxidative stress or a degenerative process, comprising administering to a subject exhibiting said skin condition an effective amount of the composition of claim 1 .

9 . A method of reducing, treating, or preventing the signs of skin aging or of reducing the appearance of signs of skin aging comprising administering to a subject exhibiting said skin condition an effective amount of the composition of claim 1 .

10 . A method of regulating or preventing a skin condition wherein the skin condition is associated with visible and/or tactile discontinuities of the skin, comprising administering to a subject exhibiting said skin condition, an effective amount of the composition of claim 1 .

11 . The method of claim 10 , wherein the visible and /or tactile discontinuities are associated with aging, age-related damage or damage resulting from extrinsic factors.

12 . The method of claim 10 , wherein the visible discontinuities of the skin are associated with pigmentation disorders.

13 . The method of claim 12 , wherein the pigmentation disorders are selected from uneven pigmentation, hyperpigmentation, age spots, vitiligo, and melasma.

14 . A method for preventing, lightening or reducing the appearance of visible and/or tactile discontinuities of the skin comprising administering to a subject exhibiting said skin conditions an effective amount of the composition of claim 1 .

15 . The method of claim 14 , where the visible and/or tactile discontinuities of the skin are selected from the group consisting of increased pore size, flaking, mottling, wrinkles, furrows, and skin lines.

16 . A method for preventing, lightening or reducing the appearance of visible discontinuities of the skin, comprising administering to a subject exhibiting said skin conditions an effective amount of the composition of claim 1 .

17 . The method of claim 16 , wherein the visible discontinuities of the skin are selected from the group consisting of uneven pigmentation, hyperpigmentation, age spots, vitiligo and melasma.

18 . A method of regulating or preventing a skin condition wherein the skin condition is associated with visible and/or tactile discontinuities of the skin, while concurrently reducing, treating, or preventing the signs of skin aging, comprising administering to a subject exhibiting said skin condition, an effective amount of the composition of claim 1 .

19 . The method of claim 18 , wherein the visible discontinuities of the skin are selected from uneven pigmentation, hyperpigmentation, age spots, vitiligo and melasma.

20 . The method of claim 18 , wherein the visible discontinuities of the skin are a result from harmful ultraviolet radiation, pollution and other environmental insults, stress and fatigue.

21 . Use of a composition comprising a skin care composition of claim 1 in the manufacture of a cosmetic or dermatological composition for treating a mammalian subject of a dermatologic condition to prevent, regulate or treat signs of skin aging or skin pigmentation, or to reduce the appearance of skin aging or skin pigmentation.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2011
From: EDISON PHARMACEUTICALS, INC.
To: AMPERE LIFE SCIENCES, INC.
Reel/Frame 027028/0579 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2009
From: HINMAN, ANDREW W.; MILLER, GUY M.
To: EDISON PHARMACEUTICALS, INC.
Reel/Frame 023087/0909 →